tbuckley/cabot-search huggingface dataset:
FRI0032 Incidence of clinically relevant infections associated with rheumatoid arthritis (ra) therapies
Authors: O Gluck, J Tesser, G Lawless, SW Wade, GA Goldberg, D Batra, P Kadlubek
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To evaluate incidence of clinically significant infections in RA patients treated with various RA therapies. <h3>Methods</h3> Retrospective analysis of linked medical and outpatient pharmacy claims from 10/98–9/99 was conducted using a large managed care database (Protocare Sciences). Patients age 35 and older, having at least 2 claims more than 20 days apart with an ICD-9CM diagnosis for RA were selected for analysis. RA therapies, including anti-inflammatory agents, steroids, DMARDS, and other systemic anti-arthritic agents were classified and clinically significant infections were identified. Comparisons of infection rates between various therapies were assessed using Incidence Density Ratios. <h3>Results</h3> Most of the 2,443 RA patients (86%) received drug therapy specific for RA during the study period. Overall, 1,207 patients (49%) had at least one infection, 783 patients (32%) had at least one upper Respiratory Infection (RI), and 716 patients (29%) had at least one non-RI. A greater proportion of patients who received direct RA therapy experienced an upper RI compared to those patients who did not (32.8% vs. 27.8%). Patients had a statistically higher occurrence of infections for pneumonia and bronchitis during use of potentially immunomodulating therapy (IMT). Subgroup analysis of patients receiving IMT by steroid exposure is presented Table 1. Incidence Density Ratios (95% CI): <h3>Conclusion</h3> Infections were common in patients on RA therapies with nearly half of all patients experiencing at least one infection during the 12 months studied. Selection of therapy associated with infections should be considered in the overall management of patients with rheumatoid arthritis.
Abstract 15607: Status of Dyslipidemia and Associated Risk Factors in Eastern China
Authors: Wei Yu, Shiyun Hu, Xiaoling Xu, Jing Yan, Fang Ding, Xuan Chen, Meifang Su, Zhenjun Lou, Qiuliang Zhu, Zhenping Hu, Junfei He, Jianling Shao, Zugui Zhang
Journal: Circulation (2019)

Introduction: The prevalence of dyslipidemia continues to increase worldwide, including in China, but recent data are lacking. Hypothesis: A survey was conducted between 2015 and 2016 to assess the...
Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Authors: Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Journal: Journal of Clinical Oncology (2019)

Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations.
Improved Outcome with Pulses of Vincristine and Steroids in Continuation Therapy of Children with Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC Randomized Phase III Trial 58951
Authors: Barbara De Moerloose, Stefan Suciu, Yves Bertrand, Francoise Mazingue, Alain Robert, Anne Uyttebroeck, Karima Yacouben, Alina Ferster, Geneviève Margueritte, Patrick Lutz, Martine Munzer, Nicolas Sirvent, Lucilia Norton, Patrick Boutard, Dominique Plantaz, Frédéric Millot, Pierre Philippet, Liliana Baila, Yves Benoit, Jacques Otten
Journal: Blood (2008)
Response to: ‘NCF1-339 polymorphism and systemic lupus erythematosus’ by Joob and Wiwanitkit
Authors: Carl Petrus Linge, Anders Bengtsson
Journal: Annals of the Rheumatic Diseases (2019)

In the comment by Joob and Wiwanitkit,1 questions are raised regarding the role of the NCF1-339 rs201802880 polymorphism in systemic lupus erythematosus (SLE) in our recent publication.2 One concern relates to the possibility of a molecular weight change due to the polymorphism and if this could alter phenotypic expression. Studies of functional effects of the polymorphism in question have been demonstrated both in this report as well as in earlier …
Health care utilization and treatment patterns for patients (pts) with gastric cancer (GC) in China.
Authors: Jeff Jianfei, Wenmin Du, Laura Chu, Xiaopei Wang, Jane Pruemer
Journal: Journal of Clinical Oncology (2013)

e15185 Background: GC is the third most common cancer in China with ~0.3 million deaths and 0.4 million new cases annually. Objective: To describe treatment patterns and survival for pts with GC, and to assess treatment outcomes and associated factors including health insurance coverage, gastric-intestinal disease, clinical comorbidities and family genetic or demographic factors. Methods: A retrospective cohort study was conducted. Primary data sources were medical records collected from multiple major Shanghai medical centers with timeframe of Jan2004 - Mar2010. Treatment outcomes included ‘improvement’ and ‘recovery or cure’ (as documented in the pts’ record), and death. Classical logistic regression and COX proportional hazard regression analysis were performed to assess the relationship between health outcomes and associated factors. Results: A total of 2249 GC pts were identified with mean age 65.9 and 36% female. Average follow-up was 26.3 months since GC index date (1 st GC diagnosis date). During the study period, 518 (23%) pts died. GC treatments included surgical procedure (28%), radiation (2%), chemotherapy (14%), and traditional Chinese medicine/herbal regimens (21%). Major chemotherapy included 5-FU, cisplatin, etoposide, leucovorin, mitomycin, oxaliplatin, and semustine. From multivariable models, pts more likely to achieve recovery or cure were those who received surgical procedures (OR=15.0, 95% CI 11.3-19.9), radiation (OR=2.4, 95% CI 1.2-4.9), any chemotherapy (OR=2.7, 95% CI 1.9-3.9), and were covered by public health insurance (OR=3.5, 95% CI 2.3-5.3) or collaborative insurance (OR=3.5, 95% CI 2.1-5.8). Higher risk of mortality was significantly associated with key factors like advanced age (OR=1.0, 95% CI 1.0-1.0), late-stage cancer (OR=9.8, 95% CI 5.1-19.0), and liver disease (OR=1.9, 95% CI 1.4-2.6). A lower risk of mortality was associated with surgical procedure treatment (OR=0.6, 95% CI 0.5-0.7) and chemotherapy (OR=0.6, 95% CI 0.4-0.9). Conclusions: Multiple treatment regimens for GC are available in China. Surgical procedure, chemotherapy, TCM/herbal, and health insurance coverage are associated with positive treatment outcome and survival duration.
Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis
Authors: Pablo Fernandez-Penas, Matteo Carlino, Victoria Atkinson, Melinda Telli, Rohit Joshi, Sajev Thomas, Katy Tsai, Rachel Roberts-Thomson, Andrew Haydon, Andrew Mant, Tom Van Hagen, Katharine Cuff, Bianca Devitt, Igor Puzanov, Marcus Butler, Catalin Mihalcioiu, Hatem Soliman, John Hyngstrom, Mecker Moller, Gregory Daniels, Eric Whitman, Erica Browning, Reneta Hermiz, Lauren Svenson, Jack Lee, Donna Bannavong, Jendy Sell, Kellie Malloy, David Canton, Christopher Twitty, Adil Daud, Alain Algazi
Journal: Journal for ImmunoTherapy of Cancer (2019)
Development of a Cardio-Oncology Program in a Community Hospital
Authors: Deborah W. Sundlöf, Brijesh D. Patel, Kelly C. Schadler, Ross G. Biggs, Cheri A. Silverstein Fadlon, Paul S. Corotto, Sameer Tolay, Ahmed J. Nadeem, Ranju Gupta, Nadeem V. Ahmad
Journal: JACC CardioOncology (2019)

The intersection between cardiovascular disease and cancer care is relevant to patients with cancer across the health care system. Cancer and cardiovascular disease are the leading causes of death in the United States ([1][1]). In the United States, 48% of adults have cardiovascular disease ([2][2
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis
Authors: Michele Boldrini, Francesco Cappelli, Liza Chacko, Maria Alejandra Restrepo-Cordoba, Angela Lopez-Sainz, Alberto Giannoni, Alberto Aimo, Andrea Baggiano, Ana Martinez-Naharro, Carol Whelan, Cristina Quarta, Claudio Passino, Vincenzo Castiglione, Vladyslav Chubuchnyi, Valentina Spini, Claudia Taddei, Giuseppe Vergaro, Aviva Petrie, Luis Ruiz-Guerrero, Vanessa Moñivas, Susana Mingo-Santos, Jesus G. Mirelis, Fernando Dominguez, Esther Gonzalez-Lopez, Stefano Perlini, Gianluca Pontone, Julian Gillmore, Philip N. Hawkins, Pablo Garcia-Pavia, Michele Emdin, Marianna Fontana
Journal: JACC. Cardiovascular imaging (2019)
High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma
Authors: Hajime Senjo, Kenji Hirata, Koh Izumiyama, Koichiro Minauchi, Kazuo Itoh, Eriko Tsukamoto, Akio Mori, Shuichi Ota, Daigo Hashimoto, Takanori Teshima
Journal: Blood (2019)
Abstract 16768: Effects of Meditation and Cardiac Rehabilitation on Myocardial Blood Flow by Quantitative Positron Emission Tomography: A Pilot Trial in African American Patients With Coronary Heart Disease
Authors: Robert Schneider, Sabahat Bokhari, Maxwell Rainforth, John Salerno, Carolyn King, Sanford Nidich
Journal: Circulation (2017)

Introduction: Coronary heart disease (CHD) rates are disproportionately high in African Americans, in part related to psychosocial stress. The role of stress reduction in cardiac rehabilitation for...
The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease
Authors: Alberto J. Espay, Robert A. Hauser, Melissa J. Armstrong
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Final Results of Phase II Trial (MIRACULUM) of the Novel PD-1 Inhibitor Prolgolimab in Patients with Advanced Melanoma
Authors: S. Tjulandin, M. Fedyanin, L. Demidov, V. Moiseyenko, S. Protsenko, S. Odintsova, T.Y. Semiglazova, R. Zukov, S. Lazarev, A. Andreev, M. Nechaeva, J. Makarova, N. Fadeeva, A. Tarasova, O. Kozlova, M. Shustova, A. Garipov, R. Ivanov
Journal: Annals of Oncology (2019)
Associations of Regional Brain Structural Differences With Aging, Modifiable Risk Factors for Dementia, and Cognitive Performance
Authors: Hideaki Suzuki, Ashwin V. Venkataraman, Wenjia Bai, Florian Guitton, Yike Guo, Abbas Dehghan, Paul M. Matthews
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Identifying brain regions associated with risk factors for dementia could guide mechanistic understanding of risk factors associated with Alzheimer disease (AD). <h3>Objectives</h3> To characterize volume changes in brain regions associated with aging and modifiable risk factors for dementia (MRFD) and to test whether volume differences in these regions are associated with cognitive performance. <h3>Design, Setting, and Participants</h3> This cross-sectional study used data from UK Biobank participants who underwent T1-weighted structural brain imaging from August 5, 2014, to October 14, 2016. A voxelwise linear model was applied to test for regional gray matter volume differences associated with aging and MRFD (ie, hypertension, diabetes, obesity, and frequent alcohol use). The potential clinical relevance of these associations was explored by comparing their neuroanatomical distributions with the regional brain atrophy found with AD. Mediation models for risk factors, brain volume differences, and cognitive measures were tested. The primary hypothesis was that common, overlapping regions would be found. Primary analysis was conducted on April 1, 2018. <h3>Main Outcomes and Measures</h3> Gray matter regions that showed relative atrophy associated with AD, aging, and greater numbers of MRFD. <h3>Results</h3> Among 8312 participants (mean [SD] age, 62.4 [7.4] years; 3959 [47.1%] men), aging and 4 major MRFD (ie, hypertension, diabetes, obesity, and frequent alcohol use) had independent negative associations with specific gray matter volumes. These regions overlapped neuroanatomically with those showing lower volumes in participants with AD, including the posterior cingulate cortex, the thalamus, the hippocampus, and the orbitofrontal cortex. Associations between these MRFD and spatial memory were mediated by differences in posterior cingulate cortex volume (β = 0.0014; SE = 0.0006;<i>P</i> = .02). <h3>Conclusions and Relevance</h3> This cross-sectional study identified differences in localized brain gray matter volume associated with aging and MRFD, suggesting regional vulnerabilities. These differences appeared relevant to cognitive performance even among people considered cognitively healthy.
Image Gallery: Onychomadesis in linear IgA bullous dermatosis
Authors: H. Wang, X. Wang, B. Yang, H. Liu, F. Zhang
Journal: British Journal of Dermatology (2019)

Funding sources: none. Conflicts of interest: none to declare. Dear Editor, A 5‐year‐old boy came to dermatology with tense blisters on his face, trunk and extremities of 2 months' duration. All of his fingernail plates had separated from the nail matrices (a). A diagnosis of linear IgA bullous dermatosis was made based on the pathological and immunopathological findings (c). The lesions were cleared with a 4‐month course of dapsone and methylprednisolone (b). To our knowledge, this is the first reported case of linear IgA bullous dermatosis coexisting with onychomadesis. The nail changes might have been due to inflammation of the nail matrix caused by IgA antibodies acting against target autoantigens.1
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Authors: Szymon Klossowski, Hongzhi Miao, Katarzyna Kempinska, Tao Wu, Trupta Purohit, Eungi Kim, Brian M. Linhares, Dong Chen, Gloria Jih, Eric Perkey, Huang Huang, Miao He, Bo Wen, Yi Wang, Ke Yu, Stanley Chun-Wei Lee, Gwenn Danet-Desnoyers, Winifred Trotman, Malathi Kandarpa, Anitria Cotton, Omar Abdel-Wahab, Hongwei Lei, Yali Dou, Monica Guzman, Luke Peterson, Tanja A. Gruber, Sarah M. Choi, Duxin Sun, Pingda Ren, Lian-Sheng Li, Yi Liu, Francis J. Burrows, Ivan Maillard, Tomasz Cierpicki, Jolanta Grembecka
Journal: Journal of Clinical Investigation (2019)

The protein-protein interaction between menin and mixed lineage leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the nucleophosmin 1 (NPM1) gene. As a step toward clinical translation of menin-MLL1 inhibitors, we report development of MI-3454, a highly potent and orally bioavailable inhibitor of the menin-MLL1 interaction. MI-3454 profoundly inhibited proliferation and induced differentiation in acute leukemia cells and primary patient samples with MLL1 translocations or NPM1 mutations. When applied as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia, including patient-derived xenograft models, through downregulation of key genes involved in leukemogenesis. We also identified MEIS1 as a potential pharmacodynamic biomarker of treatment response with MI-3454 in leukemia, and demonstrated that this compound is well tolerated and did not impair normal hematopoiesis in mice. Overall, this study demonstrates, for the first time to our knowledge, profound activity of the menin-MLL1 inhibitor as a single agent in clinically relevant PDX models of leukemia. These data provide a strong rationale for clinical translation of MI-3454 or its analogs for leukemia patients with MLL1 rearrangements or NPM1 mutations.
Roseburia spp. Abundance Associates with Alcohol Consumption in Humans and Its Administration Ameliorates Alcoholic Fatty Liver in Mice
Authors: Boram Seo, Kyungchan Jeon, Sunghyun Moon, Kiuk Lee, Woon-Ki Kim, Hyein Jeong, Kwang Hyun Cha, Mi Young Lim, Wondae Kang, Mi-Na Kweon, Joohon Sung, Won Kim, Joo-Hong Park, GwangPyo Ko
Journal: Cell Host & Microbe (2019)
RETRACTED ARTICLE: m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5
Authors: Yi Zhang, Min Kang, Bin Zhang, Fanchao Meng, Jun Song, Hiroshi Kaneko, Fumio Shimamoto, Bo Tang
Journal: Molecular Cancer (2019)

Abstract Background Colon cancer (CC) cells can exhibit stemness and expansion capabilities, which contribute to resistance to conventional chemotherapies. Aberrant expression of CBX8 has been identified in many types of cancer, but the cause of this aberrant CBX8 expression and whether CBX8 is associated with stemness properties in CC remain unknown. Methods qRT-PCR and IHC were applied to examine CBX8 levels in normal and chemoresistant CC tissues. Cancer cell stemness and chemosensitivity were evaluated by spheroid formation, colony formation, Western blot and flow cytometry assays. RNA-seq combined with ChIP-seq was used to identify target genes, and ChIP, IP and dual luciferase reporter assays were applied to explore the underlying mechanisms. Results CBX8 was significantly overexpressed in chemoresistant CC tissues. In addition, CBX8 could promote stemness and suppress chemosensitivity through LGR5. Mechanistic studies revealed that CBX8 activate the transcription of LGR5 in a noncanonical manner with assistance of Pol II. CBX8 recruited KMT2b to the LGR5 promoter, which maintained H3K4me3 status to promote LGR5 expression. Moreover, m 6 A methylation participated in the upregulation of CBX8 by maintaining CBX8 mRNA stability. Conclusions Upon m 6 A methylation-induced upregulation, CBX8 interacts with KMT2b and Pol II to promote LGR5 expression in a noncanonical manner, which contributes to increased cancer stemness and decreased chemosensitivity in CC. This study provides potential new therapeutic targets and valuable prognostic markers for CC.
Endoscopic ultrasound-guided drainage of an abdominal abscess using a lumen-apposing metal stent
Authors: Mauro Manno, Simona Deiana, Laura Ottaviani, Sara Vavassori, Tommaso Gabbani, Paola Soriani
Journal: Endoscopy (2019)

Endoscopic ultrasound (EUS)-guided drainage using a lumen-apposing metal stent (LAMS) is an emerging technique for the treatment of peripancreatic fluid collections, acute cholecystitis in patients unfit for surgery, and malignant distal obstructive jaundice after failed endoscopic retrograde cholangiopancreatography (ERCP) [1]. Moreover, it is a promising treatment for the drainage of mediastinal, liver, and pelvic abscesses [2].
Ranitidine: Injection back in stock but all oral supplies in Europe still suspended
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Ranitidine injections are back in stock and supplies are available to order from wholesalers, the Department of Health and Social Care has said.1

The alert, given on 20 December, said that the injections are in stock after the Medicines and Healthcare Products Regulatory Agency granted approval for the release of Alliance Pharmaceutical’s quarantined stock on 5 December 2019. They …
NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload
Authors: Moritz Schnelle, Iain Sawyer, Narayana Anilkumar, Belal A Mohamed, Daniel A Richards, Karl Toischer, Min Zhang, Norman Catibog, Greta Sawyer, Héloïse Mongue-Din, Katrin Schröder, Gerd Hasenfuss, Ajay M Shah
Journal: Cardiovascular Research (2019)

Abstract Aims Chronic pressure or volume overload induce concentric vs. eccentric left ventricular (LV) remodelling, respectively. Previous studies suggest that distinct signalling pathways are involved in these responses. NADPH oxidase-4 (Nox4) is a reactive oxygen species-generating enzyme that can limit detrimental cardiac remodelling in response to pressure overload. This study aimed to assess its role in volume overload-induced remodelling. Methods and results We compared the responses to creation of an aortocaval fistula (Shunt) to induce volume overload in Nox4-null mice (Nox4−/−) vs. wild-type (WT) littermates. Induction of Shunt resulted in a significant increase in cardiac Nox4 mRNA and protein levels in WT mice as compared to Sham controls. Nox4−/− mice developed less eccentric LV remodelling than WT mice (echocardiographic relative wall thickness: 0.30 vs. 0.27, P &amp;lt; 0.05), with less LV hypertrophy at organ level (increase in LV weight/tibia length ratio of 25% vs. 43%, P &amp;lt; 0.01) and cellular level (cardiomyocyte cross-sectional area: 323 µm2 vs. 379 μm2, P &amp;lt; 0.01). LV ejection fraction, foetal gene expression, interstitial fibrosis, myocardial capillary density, and levels of myocyte apoptosis after Shunt were similar in the two genotypes. Myocardial phospho-Akt levels were increased after induction of Shunt in WT mice, whereas levels decreased in Nox4−/− mice (+29% vs. −21%, P &amp;lt; 0.05), associated with a higher level of phosphorylation of the S6 ribosomal protein (S6) and the eIF4E-binding protein 1 (4E-BP1) in WT compared to Nox4−/− mice. We identified that Akt activation in cardiac cells is augmented by Nox4 via a Src kinase-dependent inactivation of protein phosphatase 2A. Conclusion Endogenous Nox4 is required for the full development of eccentric cardiac hypertrophy and remodelling during chronic volume overload. Nox4-dependent activation of Akt and its downstream targets S6 and 4E-BP1 may be involved in this effect.